Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
NVTA - Invitae Corporation
Market Cap 323.24M P/E - EPS this Y 51.80% Ern Qtrly Grth -
Income -1.44B Forward P/E -1.07 EPS next Y -6.60% 50D Avg Chg 2.00%
Sales 481.58M PEG 0.00 EPS past 5Y - 200D Avg Chg -31.00%
Dividend N/A Price/Book N/A EPS next 5Y 8.00% 52W High Chg -86.00%
Recommedations 3.50 Quick Ratio 2.14 Shares Outstanding 286.49M 52W Low Chg 22.00%
Insider Own 1.51% ROA -23.70% Shares Float 284.38M Beta 1.59
Inst Own 47.96% ROE - Shares Shorted/Prior 67.76M/59.35M Price 1.24
Gross Margin 27.13% Profit Margin -299.14% Avg. Volume 7,944,709 Target Price 0.53
Oper. Margin -84.87% Earnings Date Feb 26 Volume 6,620,427 Change -6.06%
Healthcare | Diagnostics & Research | United States
About Invitae Corporation

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California. On February 13, 2024, Invitae Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey.

Invitae Corporation News
02/15/24 Invitae gets court approval for five-month bankruptcy sale
02/13/24 Genetic test maker Invitae files for bankruptcy protection in US
02/13/24 Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process
02/07/24 Invitae hires advisers, considers bankruptcy: WSJ
02/05/24 SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy
02/05/24 SoftBank-Backed Medical Genetics Company Invitae Prepares for Bankruptcy
01/30/24 Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
01/29/24 Is Invitae Stock a Buy Now?
01/22/24 Invitae Completes Sale of Reproductive Health Assets to Natera
01/22/24 Invitae sells reproductive health assets amid liquidity concerns
12/22/23 Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock
12/13/23 Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts
12/13/23 What Makes Invitae (NVTA) a New Buy Stock
12/11/23 3 Cathie Wood Stocks to Sell Before It’s Too Late
12/05/23 Better Growth Stock: CRISPR Therapeutics vs. Invitae
11/09/23 Invitae Corporation (NYSE:NVTA) Q3 2023 Earnings Call Transcript
11/09/23 Q3 2023 Invitae Corp Earnings Call
11/09/23 Invitae (NVTA) Q3 2023 Earnings Call Transcript
11/08/23 Invitae Corp (NVTA) Reports Mixed Third Quarter 2023 Financial Results Amid Operational Adjustments
11/08/23 Invitae (NVTA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Nussbaum Robert L Chief Medical Office.. Chief Medical Officer Jun 13 Sell 1.3770 7,086 9,757 569,345 06/15/23
Wen Yafei Chief Financial Offi.. Chief Financial Officer May 16 Sell 1.1993 43,452 52,112 700,297 05/24/23
George Sean E Director Director Dec 16 Sell 2.06 55,979 115,317 732,677 12/20/22
Brida Thomas See remarks See remarks Aug 16 Sell 4.5503 7,048 32,071 386,267 08/18/22
Nussbaum Robert L Chief Medical Office.. Chief Medical Officer Aug 16 Sell 4.5503 7,048 32,071 396,532 08/18/22
WERNER ROBERT F. Chief Accounting Off.. Chief Accounting Officer May 17 Sell 3.61 10,102 36,468 201,909 05/19/22
Knight Kenneth D. Chief Operating Offi.. Chief Operating Officer May 17 Sell 3.8101 28,295 107,807 518,895 05/19/22
Brida Thomas See Remarks See Remarks May 17 Sell 3.8101 6,098 23,234 393,315 05/19/22
George Sean E President & CEO President & CEO May 17 Sell 3.8101 18,296 69,710 794,691 05/19/22
Wen Yafei Chief Financial Offi.. Chief Financial Officer May 17 Sell 3.8101 17,042 64,932 344,374 05/19/22
Nussbaum Robert L Chief Medical Office.. Chief Medical Officer May 17 Sell 3.8101 6,098 23,234 403,580 05/19/22
George Sean E President & CEO President & CEO Mar 12 Sell 6.69 31,389 209,992 812,987 03/16/22
Brida Thomas General Counsel General Counsel Mar 12 Sell 6.69 17,987 120,333 229,739 03/16/22
Wen Yafei Chief Financial Offi.. Chief Financial Officer Mar 12 Sell 6.69 3,289 22,003 136,416 03/16/22
Nussbaum Robert L Chief Medical Office.. Chief Medical Officer Mar 12 Sell 6.69 19,588 131,044 241,167 03/16/22
Stueland Katherine Chief Commercial Off.. Chief Commercial Officer Jun 16 Sell 31.6 20,340 642,744 214,231 06/16/21
George Sean E President & CEO President & CEO Apr 23 Sell 36.55 3,675 134,321 669,920 04/23/21
Stueland Katherine Chief Commercial Off.. Chief Commercial Officer Apr 15 Sell 40.26 19,893 800,892 189,871 04/15/21
George Sean E President & CEO President & CEO Mar 05 Sell 37.62 3,675 138,254 633,668 03/05/21
Brida Thomas General Counsel General Counsel Mar 03 Sell 42.93 5,000 214,650 202,876 03/03/21
George Sean E President & CEO President & CEO Jan 22 Option 8.7 5,000 43,500 646,018 01/22/21
George Sean E President & CEO President & CEO Jan 22 Sell 54.52 8,675 472,961 637,343 01/22/21
Stueland Katherine Chief Commercial Off.. Chief Commercial Officer Jan 15 Option 10.94 4,199 45,937 207,251 01/15/21
Stueland Katherine Chief Commercial Off.. Chief Commercial Officer Jan 15 Sell 51.17 4,199 214,863 203,052 01/15/21
Myers Jason W. Director Director Dec 28 Sell 50.65 174,152 8,820,799 410,597 12/28/20
Myers Jason W. Director Director Dec 23 Sell 50.77 224,965 11,421,473 584,749 12/23/20
George Sean E President & CEO President & CEO Dec 23 Sell 52.85 3,675 194,224 631,018 12/23/20
Myers Jason W. Director Director Dec 18 Sell 47.69 253,912 12,109,063 809,714 12/18/20
AGUIAR ERIC Director Director Dec 18 Option 24.16 10,000 241,600 10,000 12/18/20
AGUIAR ERIC Director Director Dec 18 Sell 51.1 10,000 511,000 12/18/20
Stueland Katherine Chief Commercial Off.. Chief Commercial Officer Dec 16 Sell 57.97 34,300 1,988,371 203,052 12/16/20
WERNER ROBERT F. Chief Accounting Off.. Chief Accounting Officer Nov 27 Sell 49.59 2,427 120,355 58,398 11/27/20
Guyer Shelly D Chief Financial Offi.. Chief Financial Officer Nov 20 Sell 47.09 3,000 141,270 224,520 11/20/20
Brida Thomas General Counsel General Counsel Nov 18 Sell 46.17 5,000 230,850 207,876 11/18/20
AGUIAR ERIC Director Director Nov 18 Option 9.61 30,000 288,300 30,000 11/18/20
AGUIAR ERIC Director Director Nov 18 Sell 46.71 30,000 1,401,300 11/18/20